Elsevier

The Journal of Pediatrics

Volume 145, Issue 3, September 2004, Pages 403-405
The Journal of Pediatrics

Clinical and Laboratory Observations
Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1–infected children

https://doi.org/10.1016/j.jpeds.2004.04.048Get rights and content

Abstract

Differences in virologic response were compared in 32 HIV-infected children with a nelfinavir trough concentration either below (n = 7) or above (n = 25) 0.8 mg/L. Virologic response at week 48 was observed in 29% of children with subtherapeutic nelfinavir troughs versus 80% in children with therapeutic nelfinavir troughs (P = .02).

Section snippets

Methods

This pharmacokinetic study was conducted as a substudy of the Pediatric European Network for Treatment of AIDS (PENTA) 5 trial. Details on PENTA 5 are provided elsewhere.6

A nelfinavir trough concentration was measured between week 20 and week 80 in the morning just before the next intake of medication. A nelfinavir trough concentration below 0.8 mg/L was considered subtherapeutic, based on a recent consensus document for target trough concentrations to be used in therapeutic drug monitoring

Results

A total of 44 children participated in this substudy. For various reasons, data from 12 children were not evaluable: insufficient sample volume (n = 1), once-daily use of nelfinavir (n = 1), inadvertent intake of nelfinavir before sampling (n = 6), undetectable nelfinavir troughs, suggesting nonadherence (n = 4) (Table).

A total of 7 children (22%) had a concentration below 0.8 mg/L, ranging from 0.10 to 0.57 mg/L. The remaining 25 children all had a nelfinavir trough concentration above 0.8 mg/L, with

Discussion

This pharmacokinetic substudy of PENTA 5 in treatment-naive HIV-infected children confirms previous observations of a positive association between nelfinavir plasma levels and virologic response in HIV-infected adults.1., 2., 3., 4. Children who had a nelfinavir trough concentration >0.8 mg/L had a better virologic response than children with a value below this threshold (Figure). These data are consistent with the concept that the advised target concentration of 0.8 mg/L for a nelfinavir

References (11)

  • I. Pellegrin et al.

    Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)

    AIDS

    (2002)
  • R.M.W. Hoetelmans et al.

    The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy

    AIDS

    (1998)
  • W.G. Powderly et al.

    Predictors of optimal virological response to potent antiretroviral therapy

    AIDS

    (1999)
  • D.M. Burger et al.

    Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations

    Ther Drug Monit

    (2003)
  • D. Burger et al.

    Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

    AIDS

    (2003)
There are more references available in the full text version of this article.

Cited by (24)

  • Pharmacokinetic-Pharmacodynamic Basis of Optimal Antibiotic Therapy

    2012, Principles and Practice of Pediatric Infectious Diseases, Fourth Edition
View all citing articles on Scopus
View full text